picobella homevisionsciencepipelineteamcontact
A biotechnology company with a comprehensive genomics approach to cancer

The company focuses on identifying the genes of the targets and cooperating signaling pathways that cause or promote the development of cancer. Picobella intends to capitalize on these discoveries by (1) offering access to its comprehensive portfolio of oncogene and tumor suppressor gene targets, together with ancillary biological and pathological data; (2) simultaneously developing diagnostic and prognostic assays, to be sold through collaborating partner(s), and as guidance to (3) developing therapeutic drugs in-house. In addition to developing therapeutic drugs on a target-by-target approach, Picobella will also use its data on cooperative signaling pathways to aid in the development of combinations of drugs designed to attack the multiple targets responsible for cancer development.